Theralase raises up to C$4M in private placement to fund cancer and virus treatment trials

Theralase Technologies Inc. announced a private placement to raise between C$3M and C$4M by issuing units at C$0.24 each, including common shares and warrants. The funds will support Phase II bladder cancer trials, toxicology studies for intravenous cancer treatments, and general corporate needs, with additional virus treatment studies if maximum funds are raised. The offering closes May 20, 2026, subject to regulatory approvals, with Research Capital Corporation acting as sole agent. This financing aims to advance Theralase's development of energy-activated molecules targeting cancer, bacteria, and viruses.